Release Date: May 08, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Liquidia Corp (NASDAQ:LQDA) is preparing for the potential launch of its first internally developed commercial product, Erepia, which targets pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company received a favorable court ruling dismissing United Therapeutics' cross claim, removing legal barriers to Erepia's potential final approval. Liquidia Corp (NASDAQ:LQDA) has a strategic focus on developing a best-in-class product profile for Erepia, emphasizing its tolerability, titratability, and ease of use. The company has a robust sales and medical affairs team with extensive experience in rare diseases, preparing for Erepia's market launch. Liquidia Corp (NASDAQ:LQDA) has established strong relationships with payers, ensuring broad access to Erepia post-launch.

Negative Points

Revenue for the first quarter of 2025 was only slightly higher than the previous year, indicating limited growth. The company reported a net loss of $38.4 million for the quarter, an increase from the previous year's loss. General and administrative expenses increased significantly by 48%, driven by higher personnel costs and legal fees. There is uncertainty regarding potential legal actions from United Therapeutics, which could impact Erepia's launch. The company faces challenges in converting patients from existing therapies to its new dry powder formulation, as seen with competitors.

Q & A Highlights

Warning! GuruFocus has detected 12 Warning Signs with LQDA.

Q: Do you believe United Therapeutics has any injunctive value left on the cross claim that was dismissed last week? Also, what is your reaction to the dismissal without prejudice versus with prejudice? A: (Rusty Schndler, General Counsel) There is currently no ongoing proceeding where United Therapeutics is seeking to prevent the FDA from approving Erepia or to stop its launch. The dismissal was without prejudice, meaning they could potentially refashion their argument, but they can't return with the same argument. We are prepared to address any future actions they might take.

Q: Could you provide insights into the forward-looking transition studies and any updates on L606? A: (Dr. Rajiv Sagar, Chief Medical Officer) The transition study will evaluate patients transitioning from Tyvaso to Erepia, focusing on PHLD patients. We aim to demonstrate safety and efficacy, including the ability to up-titrate doses. Regarding L606, we are preparing to initiate a global study with over 300 patients by the end of the year.

Story Continues

Q: How do you view the patient perspective on switching to a dry powder formulation, and how will the Ascent data support this? A: (Dr. Roger Jets, CEO) We believe Erepia's formulation offers better delivery to the lower airway, allowing patients to tolerate higher doses quickly. This should make it a preferred choice over existing nebulized options. The Ascent data will highlight Erepia's tolerability and efficacy, supporting its market adoption.

Q: Can you elaborate on the prescriber support team and any potential bridging programs for early patient access? A: (Scott Mumma, Chief Commercial Officer) Our team has extensive experience with prostacyclins and has developed a support program that meets the needs of healthcare providers and patients. We aim to ensure a smooth start for patients and will share more details post-approval.

Q: What are your expectations for the upcoming ATS meeting presentations, and when will the full 48-week data from the Ascent study be available? A: (Dr. Rajiv Sagar, Chief Medical Officer) We will present three posters at ATS, showcasing baseline demographics, tolerability, dosing characteristics, and exploratory endpoints like exercise capacity. The full 48-week data will be shared in due course.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments